189 related articles for article (PubMed ID: 17543428)
1. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt.
El-Sayed N; Al-Jorf S; Hennessey KA; Salama M; Watkins MA; Abdelwahab JA; Pallansch MA; Gary H; Wahdan MH; Sutter RW
Vaccine; 2007 Jun; 25(27):5062-70. PubMed ID: 17543428
[TBL] [Abstract][Full Text] [Related]
2. A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan.
Habib M; Soofi S; Ali N; Sutter RW; Palansch M; Qureshi H; Akhtar T; Molodecky NA; Okayasu H; Bhutta ZA
Vaccine; 2013 Apr; 31(15):1987-93. PubMed ID: 23429005
[TBL] [Abstract][Full Text] [Related]
3. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people.
Kim HJ; Hwang S; Lee S; Kwon Y; Park K; Park YJ; Bae GR; Lee SW; Jeong YS; Hyeon JY
BMC Infect Dis; 2015 Mar; 15():164. PubMed ID: 25881203
[TBL] [Abstract][Full Text] [Related]
4. Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010.
Khetsuriani N; Pallansch MA; Jabirov S; Saparova N; Oberste MS; Wannemuehler K; Ursu P; Wassilak S; Martin R
Vaccine; 2013 Oct; 31(42):4911-6. PubMed ID: 23891502
[TBL] [Abstract][Full Text] [Related]
5. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
Chowdhary R; Dhole TN
J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
[TBL] [Abstract][Full Text] [Related]
6. Poliovirus immunity among pregnant females aged 15-44 years, Namibia, 2010.
Cardemil CV; Jonas A; Gerber S; Weldon WC; Oberste MS; Beukes A; Sawadogo S; Patel SV; Zeko S; Muroua C; Gaeb E; Wannemuehler K; Goodson JL
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S136-42. PubMed ID: 25316828
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017.
Hussain I; Mach O; Hamid NA; Bhatti ZS; Moore DD; Oberste MS; Khan S; Khan H; Weldon WC; Sutter RW; Bhutta ZA; Soofi SB
Vaccine; 2018 Apr; 36(15):1921-1924. PubMed ID: 29510918
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort.
Bolu O; Adamu U; Franka R; Umeokonkwo CD; An Q; Greby S; McDonald S; Mainou B; Mba N; Agala N; Archer WR; Braka F; Etapelong SG; Gashu TS; Siddique AR; Asekun A; Okoye M; Iriemenam N; Wiesen E; Swaminathan M; Ihekweazu C; Shuaib F
Pan Afr Med J; 2023; 45(Suppl 2):2. PubMed ID: 38370104
[TBL] [Abstract][Full Text] [Related]
9. Poliovirus neutralizing antibody levels among individuals in three regions of Ghana.
Opare JK; Akweongo P; Afari EA; Odoom JK
Ghana Med J; 2019 Jun; 53(2):170-180. PubMed ID: 31481814
[TBL] [Abstract][Full Text] [Related]
10. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
[TBL] [Abstract][Full Text] [Related]
11. Progress toward poliomyelitis eradication--Egypt, 2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2003 Mar; 52(12):252-5. PubMed ID: 12680521
[TBL] [Abstract][Full Text] [Related]
12. [German Health survey 1997/98: immune status against poliomyelitis].
Diedrich S; Claus H; Thierfelder W; Bellach BM; Schreier E
Dtsch Med Wochenschr; 2000 May; 125(19):584-8. PubMed ID: 11320716
[TBL] [Abstract][Full Text] [Related]
13. Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study.
Bianchi FP; Larocca AMV; Bozzi A; Spinelli G; Germinario CA; Tafuri S; Stefanizzi P
Vaccine; 2021 May; 39(22):2989-2994. PubMed ID: 33933314
[TBL] [Abstract][Full Text] [Related]
14. [Seroepidemiology of poliomyelitis in Mexico].
Ruiz-Gómez J; Tapia-Conyer R; Salvatierra B; Quiroz G; Magos C; Llausás A; Gutiérrez G; Sepúlveda J
Salud Publica Mex; 1992; 34(2):168-76. PubMed ID: 1321508
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria.
Giwa FJ; Olayinka AT; Ogunshola FT
Vaccine; 2012 Nov; 30(48):6759-65. PubMed ID: 23000220
[TBL] [Abstract][Full Text] [Related]
16. Immunity status against poliomyelitis in young migrants: a seroprevalence study.
Veronesi L; Colucci ME; Capobianco E; Bracchi MT; Zoni R; Palandri L; Affanni P
Acta Biomed; 2019 Sep; 90(9-S):28-34. PubMed ID: 31517887
[TBL] [Abstract][Full Text] [Related]
17. Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997-2001.
Prevots DR; Pascual FB; Angellili ML; Brayden R; Irigoyen M; Larussa P; Sawyer M; Baughman AL; Pallansch MA
Pediatr Infect Dis J; 2004 Dec; 23(12):1130-6. PubMed ID: 15626951
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of poliovirus antibodies among children in a Dominican community--Puerto Rico, 2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Jun; 54(23):580-1. PubMed ID: 15959453
[TBL] [Abstract][Full Text] [Related]
19. Is Italian population protected from Poliovirus? Results of a seroprevalence survey in Florence, Italy.
Giammanco GM; Bechini A; Urone N; Bonura F; Li Muli S; De Grazia S; Bellini I; Tiscione E; Boccalini S; Nastasi A
Hum Vaccin Immunother; 2018; 14(9):2248-2253. PubMed ID: 29771600
[TBL] [Abstract][Full Text] [Related]
20. [A seroepidemiological study on the level of immunological coverage in a nomadic population in Rome].
Porta D; Chierchini P; Bruno L; Fiore L; Cristofaro G; Amato C; Catone S; Gentili G; Sangalli M; Forastiere F
Epidemiol Prev; 1997; 21(1):48-53. PubMed ID: 9157025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
